Investigational Therapies

CD200R agonist overview

In development for atopic dermatitis.

CD200R Agonist in Development
Details

ARQ-234 is a fusion protein that serves as an agonist with high selectivity and potency for the CD200 receptor (CD200R).

  • As an immune regulatory receptor that is thought to be an important immunological checkpoint, CD200R has a pivotal role in the maintenance of immune tolerance
  • Activating receptors like CD200 are an example of checkpoint agonism that can amplify pathways that inhibit overactive immune cells and suppress unwanted immune responses
  • ARQ-234 binds to CD200R, restoring immune homeostasis by inducing inhibitory signaling on immune cells that regulate inflammation
Therapy

ARQ-234 is a CD200R agonist under investigation for the treatment of atopic dermatitis.

References

Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd. News release. Arcutis Biotherapeutics, Inc; September 7, 2022.

This website is intended for US healthcare professionals only. There may be information included that pertains to an investigational therapy or formulation that has not yet been approved for use in your country. The safety and efficacy of investigational therapies and/or formulations and/or uses have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. This information is as of 12/2023 to the best of the Company’s knowledge and Arcutis assumes no obligation to update this information.

© 2024 Arcutis Biotherapeutics, Inc. All rights reserved. MED-MULTI-2100006 v5.0 12/23